Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva
US10500280B2 · kind B2 · utility
3Cited by
1References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 15, 2018 |
| Grant date | Dec 10, 2019 |
| Priority date | — |
| Expiry date | Jun 15, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A composition includes a pharmaceutical dosage form configured to dinsintegrate in saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein. The dosage form includes a therapeutically effective amount of melatonin in a carrier matrix, a disintegrant, and a sufficient amount of acid to impart the pH to the saliva. The amount of disintegrant is sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.